WhiteLab Genomics

WhiteLab Genomics identified a critical bottleneck in genomic medicine: designing effective DNA and RNA therapies required months of manual laboratory work and computational analysis, making development prohibitively expensive and slow. Biotech companies and pharmaceutical researchers experienced this most acutely—they spent years optimizing single therapeutic candidates before clinical testing, with high failure rates consuming millions in R&D budgets. The problem was measurable: therapy development timelines stretched 5-7 years, and success rates remained below 10% for novel approaches. Existing alternatives—traditional wet-lab screening and basic computational modeling—were labor-intensive and produced suboptimal designs. Early validation came from conversations with drug discovery teams who immediately recognized the efficiency gains. When WhiteLab demonstrated AI-accelerated design cycles reducing optimization from months to weeks, researchers confirmed the approach addressed their most pressing constraint. Pharma partners' willingness to pilot the platform signaled genuine market demand for faster, more reliable therapy design.